Back to top
more

Addus HomeCare (ADUS)

(Delayed Data from NSDQ)

$128.72 USD

128.72
128,761

-4.31 (-3.24%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $128.78 +0.06 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (49 out of 252)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Implied Volatility Surging for Addus HomeCare (ADUS) Stock Options

Investors need to pay close attention to Addus HomeCare (ADUS) stock based on the movements in the options market lately.

Debanjana Dey headshot

3 Stocks to Watch From the Pandemic-Hit Outpatient Home Health Industry

Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. AMED, ADUS and HNGR are well poised to gain from the prospects.

Addus HomeCare (ADUS) Q2 Earnings Surpass Estimates

Addus HomeCare (ADUS) delivered earnings and revenue surprises of 1.11% and 1.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Addus HomeCare (ADUS) Reports Next Week: What You Should Expect

Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quest Diagnostics (DGX) Tops Q2 Earnings and Revenue Estimates

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 4.42% and 4.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Addus HomeCare (ADUS) Tops Q1 Earnings Estimates

Addus HomeCare (ADUS) delivered earnings and revenue surprises of 1.32% and 0.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Addus HomeCare (ADUS) Reports Next Week: Wall Street Expects Earnings Growth

Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Addus HomeCare (ADUS) Stock Jumps 6.5%: Will It Continue to Soar?

Addus HomeCare (ADUS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Tenet Healthcare (THC) Drops Plans to Spin Off Conifer Segment

Tenet Healthcare (THC) aborts its Conifer spin-off plan based on its solid business opportunities and strong pipeline prospects. It also reaffirmed its 2022 guidance.

How Much Upside is Left in Addus HomeCare (ADUS)? Wall Street Analysts Think 62%

The average of price targets set by Wall Street analysts indicates a potential upside of 61.5% in Addus HomeCare (ADUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Addus HomeCare (ADUS) Matches Q4 Earnings Estimates

Addus HomeCare (ADUS) delivered earnings and revenue surprises of 0% and 1.67%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Addus HomeCare (ADUS) Reports Next Week: Wall Street Expects Earnings Growth

Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ADUS or CHE: Which Is the Better Value Stock Right Now?

ADUS vs. CHE: Which Stock Is the Better Value Option?

Addus HomeCare (ADUS) Q3 Earnings and Revenues Lag Estimates

Addus HomeCare (ADUS) delivered earnings and revenue surprises of -2.15% and -5.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Addus HomeCare (ADUS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Addus HomeCare (ADUS) Q2 Earnings Surpass Estimates

Addus HomeCare (ADUS) delivered earnings and revenue surprises of 1.12% and -0.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Addus HomeCare (ADUS) Earnings Expected to Grow: Should You Buy?

Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Addus HomeCare (ADUS) Q1 Earnings Surpass Estimates

Addus HomeCare (ADUS) delivered earnings and revenue surprises of 4.23% and -1.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Addus HomeCare (ADUS) Q1 Earnings Expected to Decline

Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights: Addus HomeCare, LHC Group and Amedisys

The Zacks Analyst Blog Highlights: Addus HomeCare, LHC Group and Amedisys

Sapna Bagaria headshot

Biden Chips in $400B for Home Healthcare: Stocks to Watch

Biden's support to expand access to long-term care services under Medicaid bodes well for companies providing home healthcare.

Is a Surprise Coming for Addus HomeCare (ADUS) This Earnings Season?

Addus HomeCare (ADUS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Will Encompass Health (EHC) Gain From Inpatient Rehab Business?

Encompass Health (EHC) is resorting to business restructuring to focus on core growth areas, which should expand its returns.

Align (ALGN) Rides on Robust Invisalign Sales Amid Coronavirus

Align Technology's (ALGN) Invisalign clear aligner has been receiving positive feedback and holds huge long-term market potential.

CVS Health's (CVS) Front Store Sales Robust, LTC Suffers

CVS Health's (CVS) Health Care Benefits arm benefits from strong Medicare annual enrollment period.